5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.20▲ | 2.20▲ | 2.20▲ | 2.28▼ | 2.71▼ |
MA10 | 2.23▼ | 2.24▼ | 2.26▼ | 2.58▼ | 2.59▼ |
MA20 | 2.29▼ | 2.34▼ | 2.46▼ | 2.74▼ | 2.42▼ |
MA50 | 2.63▼ | 2.62▼ | 2.65▼ | 2.55▼ | 3.38▼ |
MA100 | 2.48▼ | 2.40▼ | 2.38▼ | 2.48▼ | 4.77▼ |
MA200 | 2.47▼ | 2.64▼ | 2.74▼ | 3.16▼ | 10.43▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.004▲ | -0.005▼ | -0.019▼ | -0.109▼ | 0.092▲ |
RSI | 39.884▼ | 39.729▼ | 38.886▼ | 36.098▼ | 41.899▼ |
STOCH | 30.000 | 26.806 | 21.111 | 12.073▼ | 64.843 |
WILL %R | -70.000 | -70.000 | -70.000 | -91.879▼ | -76.480▼ |
CCI | -56.680 | -54.071 | -67.781 | -86.037 | -28.628 |
CDL | $GENE Doji Candlestick Pattern Detected | Set Alert |
Saturday, April 27, 2024 02:06 AM
Opportunistic investors can still find bargains, even with the Nasdaq Composite up 49% since the start of 2023.
|
Friday, April 26, 2024 02:16 PM
The notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq. Under Nasdaq rules, the Company has 60 calendar days from receipt of the notice, or until June ...
|
Friday, April 26, 2024 01:30 PM
Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
26/04/24 | 2.20 | 2.269 | 2.1552 | 2.221 | 20,832 |
25/04/24 | 2.31 | 2.31 | 2.10 | 2.18 | 32,104 |
24/04/24 | 2.42 | 2.4571 | 2.12 | 2.25 | 28,289 |
23/04/24 | 2.41 | 2.44 | 2.26 | 2.39 | 18,129 |
22/04/24 | 2.29 | 2.413 | 2.19 | 2.37 | 23,618 |
19/04/24 | 2.40 | 2.47 | 2.13 | 2.32 | 64,337 |
18/04/24 | 3.15 | 3.20 | 2.30 | 2.44 | 89,566 |
17/04/24 | 3.28 | 3.28 | 3.10 | 3.16 | 13,533 |
16/04/24 | 3.27 | 3.30 | 3.045 | 3.17 | 28,303 |
15/04/24 | 3.38 | 3.38 | 3.21 | 3.2701 | 15,770 |
|
|
||||
|
|
||||
|
|